Your browser doesn't support javascript.
Shattering barriers toward clinically meaningful MSC therapies.
Levy, Oren; Kuai, Rui; Siren, Erika M J; Bhere, Deepak; Milton, Yuka; Nissar, Nabeel; De Biasio, Michael; Heinelt, Martina; Reeve, Brock; Abdi, Reza; Alturki, Meshael; Fallatah, Mohanad; Almalik, Abdulaziz; Alhasan, Ali H; Shah, Khalid; Karp, Jeffrey M.
  • Levy O; Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • Kuai R; Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • Siren EMJ; BWH Center of Excellence for Biomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bhere D; Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • Milton Y; BWH Center of Excellence for Biomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Nissar N; Center for Stem Cell Therapeutics and Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • De Biasio M; Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • Heinelt M; Center for Stem Cell Therapeutics and Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Reeve B; Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • Abdi R; Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.
  • Alturki M; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.
  • Fallatah M; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Almalik A; National Center of Pharmaceutical Technology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
  • Alhasan AH; KACST Center of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
  • Shah K; KACST Center of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
  • Karp JM; National Center of Pharmaceutical Technology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
Sci Adv ; 6(30): eaba6884, 2020 07.
Article in English | MEDLINE | ID: covidwho-706017
ABSTRACT
More than 1050 clinical trials are registered at FDA.gov that explore multipotent mesenchymal stromal cells (MSCs) for nearly every clinical application imaginable, including neurodegenerative and cardiac disorders, perianal fistulas, graft-versus-host disease, COVID-19, and cancer. Several companies have or are in the process of commercializing MSC-based therapies. However, most of the clinical-stage MSC therapies have been unable to meet primary efficacy end points. The innate therapeutic functions of MSCs administered to humans are not as robust as demonstrated in preclinical studies, and in general, the translation of cell-based therapy is impaired by a myriad of steps that introduce heterogeneity. In this review, we discuss the major clinical challenges with MSC therapies, the details of these challenges, and the potential bioengineering approaches that leverage the unique biology of MSCs to overcome the challenges and achieve more potent and versatile therapies.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells / Betacoronavirus Type of study: Prognostic study Limits: Humans Language: English Journal: Sci Adv Year: 2020 Document Type: Article Affiliation country: Sciadv.aba6884

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells / Betacoronavirus Type of study: Prognostic study Limits: Humans Language: English Journal: Sci Adv Year: 2020 Document Type: Article Affiliation country: Sciadv.aba6884